Akari Therapeutics PLC
akaritx.comWhat Do They Do?
Develops antibody-drug conjugates using novel payloads to treat cancer patients.
10-K for FY2025, filed Mar 30, 2026We are an oncology company developing next-generation antibody-drug conjugates (“ADCs”) built around novel, proprietary payloads utilizing…View ↗
Our lead product candidate is AKTX-101, a preclinical Trop-2–targeting ADC that combines PH1 with a proprietary non-cleavable linker and…View ↗
In addition, we have expanded our PH1-based pipeline with AKTX-102, a CEACAM5-directed ADC program that combines a novel CEACAM5-targeting…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 13, 2026
−$4.8MView ↗
- ▲ +154% (Loss)
- vs −$1.9M in Q2 FY2025
-
Aug 13, 2026
Akari began a research collaboration with Whitehawk on dual-payload ADCs
The work will evaluate Akari’s PH1 payload with Whitehawk’s topoisomerase I payload platform.
Sources
8-K, filed Aug 13, 2026
Expanded the Company’s strategic position in novel ADC payloads through a research collaboration on dual ADC payloads with Whitehawk…View ↗
From inflammation to cancer
The older report centered on nomacopan and PAS-nomacopan for autoimmune and inflammatory diseases; the latest centers on antibody-drug conjugates using a novel payload to target cancer.
20-F for FY2022, filed May 1, 2023 10-K for FY2025, filed Mar 30, 2026We are a clinical-stage biotechnology company focused on developing advanced therapies for autoimmune and inflammatory diseases involving…View ↗
Our lead product candidate, nomacopan, is a recombinant small protein derived from a protein originally discovered in the saliva of the…View ↗
Our clinical targets for nomacopan are autoimmune and inflammatory diseases where the inhibition of both C5 and LTB4 are implicated…View ↗
We are an oncology company developing next-generation antibody-drug conjugates (“ADCs”) built around novel, proprietary payloads utilizing…View ↗
We are an oncology company developing next generation ADCs designed around novel payload biology. Our platform is anchored by PH1, a…View ↗
We acquired the proprietary rights to our ADC discovery and development platform in connection with the Merger. Prior to that time, we were…View ↗
Loading...
